NYSE:VOR Vor Biopharma 5/9/2024 Earnings Report $1.60 -0.14 (-8.05%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.62 +0.01 (+0.94%) As of 09/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Vor Biopharma EPS ResultsActual EPS-$0.45Consensus EPS -$0.37Beat/MissMissed by -$0.08One Year Ago EPSN/AVor Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVor Biopharma Announcement DetailsQuarterDate5/9/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Vor Biopharma Earnings HeadlinesVor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 12, 2025 | globenewswire.comWe Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth CarefullySeptember 7, 2025 | finance.yahoo.comThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he’s kneecapped the Federal Reserve… | Banyan Hill Publishing (Ad)Vor Bio Appoints Adi Osovsky, S.J.D. as General CounselSeptember 2, 2025 | globenewswire.comVor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpointAugust 28, 2025 | msn.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA NephropathyAugust 27, 2025 | globenewswire.comSee More Vor Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vor Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vor Biopharma and other key companies, straight to your email. Email Address About Vor BiopharmaVor Biopharma (NYSE:VOR) is a clinical‐stage biotechnology company dedicated to developing allogeneic, or “off‐the‐shelf,” cell therapies for patients with hematologic malignancies. The company leverages gene‐editing technologies to engineer healthy donor hematopoietic stem cells that are resistant to targeted anti‐cancer therapies, enabling potent elimination of malignant cells while sparing normal blood cell precursors. The company’s proprietary platform focuses on knocking out specific cell surface antigens in donor stem cells, creating paired therapeutic regimens in which one agent selectively clears malignant cells expressing the target antigen and the gene‐edited cells then repopulate the bone marrow. Vor Biopharma’s lead candidate, VOR33, is designed to protect normal hematopoiesis from anti-CD33 therapies in acute myeloid leukemia, and is being advanced in clinical trials. Additional pipeline programs aim to address other myeloid antigens and leverage similar complementary logic approaches to treat a range of blood cancers. Founded in 2015 and headquartered in Cambridge, Massachusetts, Vor Biopharma operates its research and development activities from the heart of one of the world’s leading biotech hubs. The company is led by President and Chief Executive Officer Martin W. Babler, Ph.D., whose experience in cell therapy and gene editing supports Vor Biopharma’s mission to deliver curative cell therapies that address critical unmet needs in hematology.View Vor Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
